Squibb announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended ...

Bristol Myers (BMY) announced the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has ...

Bristol-Myers Squibb gets rated a hold, as I see future value in its clinical portfolio and pipeline, particularly ...

Shares of Bristol Myers Squibb Co. BMY shed 3.04% to $58.76 Tuesday, on what proved to be an all-around positive trading ...

Bristol Myers on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Breyanzi for the treatment of adults with relapsed or refractory ...

The ERISA Industry Committee, along with two other industry groups, is seeking the dismissal of the drugmaker’s PRT lawsuit ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the ...

We recently compiled a list of the 12 Best Long Term Low Risk Stocks to Buy Right Now. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against ...

Whales with a lot of money to spend have taken a noticeably bearish stance on Bristol-Myers Squibb. Looking at options history for Bristol-Myers Squibb BMY we detected 26 trades. If we consider ...

Bristol-Myers Squibb (NYSE:BMY), a global biopharmaceutical company with a market capitalization of nearly $120 billion, finds itself at a critical juncture as it navigates a complex landscape of ...

Bristol Myers Squibb (BMY) ended the recent trading session at $56.81, demonstrating a -0.58% swing from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.16%.

We recently published a list of Jim Cramer Breaks Silence On DeepSeek AI Sell-Off & Discusses These 12 Stocks.